About Iroquois-class homeodomain protein IRX-1
Iroquois-class homeodomain protein IRX-1 (IRX1) is a protein
from Homo sapiens identified by UniProt accession
P78414, 480 residues long.
MolForge cross-references it against 0 known binders and
149 disease associations.
Target properties
| Protein name | Iroquois-class homeodomain protein IRX-1 |
| UniProt accession | P78414 |
| Gene | IRX1 |
| Organism | Homo sapiens |
| Length | 480 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (149)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- body mass index · score 0.39
- Red cell distribution width · score 0.39
- waist-hip ratio · score 0.38
- body weight · score 0.38
- systolic blood pressure · score 0.36
- diastolic blood pressure · score 0.36
- vital capacity · score 0.35
- mathematical ability · score 0.34
- self reported educational attainment · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78414-F1 | alphafold | PREDICTED | 54.71 | — |
Amino-acid sequence (480 residues)
MSFPQLGYPQ YLSAAGPGAY GGERPGVLAA AAAAAAAASS GRPGAAELGG GAGAAAVTSV LGMYAAAGPY AGAPNYSAFL PYAADLSLFS QMGSQYELKD NPGVHPATFA AHTAPAYYPY GQFQYGDPGR PKNATRESTS TLKAWLNEHR KNPYPTKGEK IMLAIITKMT LTQVSTWFAN ARRRLKKENK VTWGARSKDQ EDGALFGSDT EGDPEKAEDD EEIDLESIDI DKIDEHDGDQ SNEDDEDKAE APHAPAAPSA LARDQGSPLA AADVLKPQDS PLGLAKEAPE PGSTRLLSPG AAAGGLQGAP HGKPKIWSLA ETATSPDGAP KASPPPPAGH PGAHGPSAGA PLQHPAFLPS HGLYTCHIGK FSNWTNSAFL AQGSLLNMRS FLGVGAPHAA PHGPHLPAPP PPQPPVAIAP GALNGDKASV RSSPTLPERD LVPRPDSPAQ QLKSPFQPVR DNSLAPQEGT PRILAALPSA
Explore Iroquois-class homeodomain protein IRX-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets